HIT Consultant May 4, 2021
What You Should Know:
– Today, PhysIQ Inc. announced its partnership with Johns Hopkins University, Duke University and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), to support a clinical trial to evaluate products for early treatment and post-exposure treatment of COVID-19. The 18-month study will assess disease progression and provide early indication of infection. This DOD-funded initiative will assess the role of continuous biosensor data and artificial intelligence in addressing the COVID-19 pandemic.
– Confirmed COVID-19 positive individuals and patients at high risk of exposure will wear a clinical-grade biosensor that continuously streams data to PhysIQ’s pinpointIQTM platform where advanced FDA-cleared analytics will process the raw biosensor data. In addition to capturing...